BetaLogics' in vitro beta cells

BetaLogics Venture and The University of British Columbia have developed an in vitro protocol to generate mature insulin-producing pancreatic b-like cells from human pluripotent stem cells.1 The findings mark a major milestone for the development of new cell-based therapies for diabetes.

Harvard University researchers have separately described an in vitro protocol for generating similar cells but were unable to provide commentary in time for publication.2

BetaLogics is a venture division of Johnson & Johnson's Janssen R&D LLC unit. The division's goal is to develop and commercialize stem cell products for diabetes treatment.

The BetaLogics-UBC team and other independent research groups have previously described protocols to differentiate human pluripotent stem cells into pancreatic progenitor cells in vitro. 3-7 However, these cells still need to be matured into the desired insulin-producing cells in vivo. The BetaLogics-UBC group has previously reported that diabetic mice

Read the full 1381 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE